Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas

Cox, S. J., O'Cathail, S. M. , Coles, B., Crosby, T. and Mukherjee, S. (2017) Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas. Current Oncology Reports, 19(1), 7. (doi: 10.1007/s11912-017-0559-8) (PMID:28213876) (PMCID:PMC5315732)

[img]
Preview
Text
222636.pdf - Published Version
Available under License Creative Commons Attribution.

374kB

Abstract

Survival outcomes following multimodal treatment of operable oesophageal and gastrooesophageal cancer remain disappointingly poor. Although an appreciation of the impact of both tumour location and histological subtype is now shaping the design of clinical trials, there has been a lack of consensus of the optimal neoadjuvant treatment strategy. This update article will review recent advances in the use of both neoadjuvant chemotherapy and chemoradiotherapy. The emerging role of PET imaging to direct appropriate neoadjuvant treatment regimens and the additive benefit of biological agents are also discussed.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:O'Cathail, Dr Sean
Authors: Cox, S. J., O'Cathail, S. M., Coles, B., Crosby, T., and Mukherjee, S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Current Oncology Reports
Publisher:Springer
ISSN:1523-3790
ISSN (Online):1534-6269
Published Online:17 February 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Current Oncology Reports 19(1): 7
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record